Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Ugo Testa, Germana Castelli, Elvira Pelosi
Medical Sciences (2020) Vol. 8, Iss. 1, pp. 18-18
Open Access | Times Cited: 148

Showing 1-25 of 148 citing articles:

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Muhammad Tufail, Jia-Ju Hu, Jie Liang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 18
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Yeon Hee Park, Tae‐Yong Kim, Gun Min Kim, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 12, pp. 1750-1759
Closed Access | Times Cited: 106
Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications
Amy E. McCart Reed, Emarene Kalaw, Kátia Nones, et al.
The Journal of Pathology (2018) Vol. 247, Iss. 2, pp. 214-227
Open Access | Times Cited: 85
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
Mariana Brandão, Rafael Caparica, Daniel Eiger, et al.
Annals of Oncology (2019) Vol. 30, pp. x27-x42
Open Access | Times Cited: 74
Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis
Busra Buyuk, Sha Jin, Kaiming Ye
Cellular and Molecular Bioengineering (2021) Vol. 15, Iss. 1, pp. 1-13
Open Access | Times Cited: 56
The Role of Extracellular Matrix Proteins in Breast Cancer
Arkadiusz Lepucki, Kinga Orlińska, Aleksandra Mielczarek‐Palacz, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 5, pp. 1250-1250
Open Access | Times Cited: 52
Potential miRNA Use as a Biomarker: From Breast Cancer Diagnosis to Metastasis
Euclides Jordan‐Alejandre, Alma D. Campos-Parra, Dora Luz Castro-López, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 525-525
Open Access | Times Cited: 32
Next-Generation sequencing transforming clinical practice and precision medicine
Deepali Yadav, Bhagyashri Patil‐Takbhate, Anil Khandagale, et al.
Clinica Chimica Acta (2023) Vol. 551, pp. 117568-117568
Closed Access | Times Cited: 20
Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer
Rui Sha, Xinrui Dong, Shanshan Yan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263
Nazan Gökşen Tosun, Özlem Kaplan
Breast Cancer Research and Treatment (2025)
Open Access
Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets
Tomasz Sirek, Katarzyna Król-Jatręga, Przemysław Borawski, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Overexpression of Senescence-Associated Beta-Galactosidase (SA-B-GAL) as a Prognostic Marker of Invasive Breast Carcinoma
Milena Ilić, Slobodanka Mitrović, Milica Dimitrijevic Stojanovic, et al.
Experimental and Applied Biomedical Research (EABR) (2025)
Closed Access
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Molecular Docking Appraisal of Pleurotus ostreatus Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment
Magdalene Eno Effiong, Mercy Bella-Omunagbe, Israel Sunmola Afolabi, et al.
Bioinformatics and Biology Insights (2025) Vol. 19
Open Access
Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer
Serena Mazzucchelli, F Piccotti, Raffaele Allevi, et al.
Biological Procedures Online (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 63
Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer
Olivia K. Provance, Joan Lewis-Wambi
Breast Cancer Research (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 60
Hyaluronic acid-coated chitosan nanoparticles as targeted-carrier of tamoxifen against MCF7 and TMX-resistant MCF7 cells
Fariba Nokhodi, Mehdi Nekoei, Mohammad Taghi Goodarzi
Journal of Materials Science Materials in Medicine (2022) Vol. 33, Iss. 2
Open Access | Times Cited: 30
Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
Valentina K. Todorova, Stephanie D. Byrum, Allen Gies, et al.
Current Oncology (2022) Vol. 29, Iss. 2, pp. 613-630
Open Access | Times Cited: 29
Unraveling the Role of Scutellaria baicalensis for the Treatment of Breast Cancer Using Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation
Yanqi Jiao, Chengcheng Shi, Yao Sun
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3594-3594
Open Access | Times Cited: 14
Targeting notch-related lncRNAs in cancer: Insights into molecular regulation and therapeutic potential
Raihan Siddique, Gaurav Gupta, Johar MGM, et al.
Pathology - Research and Practice (2024) Vol. 257, pp. 155282-155282
Closed Access | Times Cited: 5
Exploring neutrophil functionality in breast cancer progression: A review
Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu
Medicine (2024) Vol. 103, Iss. 13, pp. e37654-e37654
Open Access | Times Cited: 4
Metformin-loaded chitosan nanoparticles augment silver nanoparticle-induced radiosensitization in breast cancer cells during radiation therapy
Fatemeh Shiridokht, Hamed Dadashi, Somayeh Vandghanooni, et al.
Colloids and Surfaces B Biointerfaces (2024) Vol. 245, pp. 114220-114220
Closed Access | Times Cited: 4
Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression
Mustapha Abubakar, Changyuan Guo, Hela Koka, et al.
npj Breast Cancer (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 48
The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer
Hui Liu, Marcia N. Paddock, Haibin Wang, et al.
Cancer Discovery (2020) Vol. 10, Iss. 8, pp. 1226-1239
Open Access | Times Cited: 46
A Complex and Evolutive Character: Two Face Aspects of ECM in Tumor Progression
Margaux Sala, Manon Ros, Frédéric Saltel
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top